

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
April 30, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933**

**Viking Therapeutics, Inc.**

**File No. 333-197182 - CF#31311**

---

Viking Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on July 1, 2014, as amended.

Based on representations by Viking Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.12	through May 21, 2024
Exhibit 10.13	through May 21, 2016
Exhibit 10.21	through February 20, 2017
Exhibit 10.24	through May 21, 2024
Exhibit 10.29	through January 27, 2016
Exhibit 10.30	through May 21, 2024
Exhibit 10.31	through May 21, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary